Home > Boards > US Listed > Biotechs > Ocera Therapeutics (OCRX)

Still holding on OCRX in green.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
mlkrborn   Thursday, 12/12/13 03:13:53 PM
Re: None
Post # of 2794 
Still holding on OCRX in green.
Ocera Therapeutics Announces Staffing Transition
4:00p ET December 11, 2013 (GlobeNewswire)

Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzyme, which closed in July 2013. "We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."

"It has been exciting to be part of a successful merger process, from the initial concept through completion of full integration. OCR-002 has great therapeutic potential for patients with liver disease, which is an important and growing market," said David Moore. "However, my background lies in sales and marketing, and I plan to return to working with commercial stage products."

In addition, as part of the transition of Ocera's corporate headquarters to Palo Alto, CA, Rhonda L. Stanley, Ocera's controller and principal accounting officer will be leaving Ocera. Jeryl L. Hilleman, Ocera's chief financial officer will assume the role of principal accounting officer effective immediately and a controller has been hired in Palo Alto.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger which has been granted Orphan Disease and Fast Track status from the FDA to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. For additional information, please see www.ocerainc.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences